Tafasitamab Plus Lenalidomide/Rituximab Improves PFS in Relapsed/Refractory Follicular Lymphoma
Tafasitamab plus lenalidomide and rituximab improved median PFS vs lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma.
Related Articles
China’s NMPA Grants Breakthrough Therapy Designation to Savolitinib Plus Osimertinib in EGFR+ NSCLC
Savolitinib plus osimertinib received breakthrough therapy designation in China for pretreated, locally advanced or metastatic EGFR-positive NSCLC with MET amplification.
Selinexor Plus Ruxolitinib Displays Activity in Ruxolitinib-Pretreated Myelofibrosis
Selinexor plus ruxolitinib showed activity in patients with myelofibrosis who were treated with ruxolitinib.
Survivor Auctions | eBay Stores
SURVIVOR launches a new chapter when the Emmy Award-winning series returns on Wednesdays. Stranded in the beautiful islands of Fiji, these 18 determined new castaways…
Unpacking Key Data From the 2024 ASH Annual Meeting: With Andre Goy, MD
Andre Goy, MD, discusses top hematologic oncology research from the 2024 ASH Annual Meeting.
Real-World Outcomes With Durvalumab Plus Chemotherapy for Advanced Biliary Tract Cancer Comparable to Pivotal Trial – Oncology Nurse Advisor
A real-world study sought to measure survival outcomes against the results of a pivotal clinical trial on the effectiveness of durvalumab plus chemotherapy.
Meet Dr. Toni K. Choueiri
Dr. Toni K. Choueiri shares how hard work and focus keeps him from getting discouraged or giving up when times get hard.
Newly diagnosed Diagnosed mHSPC: Goals of Therapy
Evan Y. Yu, MD, discusses how the goals of therapy for a patient with newly- diagnosed metastatic hormone-sensitive prostate cancer are to control disease progression,…
China’s Leapfrog in New Drug Development
China has made significant strides in drug development over the past two decades, transitioning from being a producer of generic drugs to a…
How Ohio State experts brought us closer to a cancer-free world in 2024
2024 was a year of breakthroughs in cancer care, research and knowledge at Ohio State, where oncology experts look ahead to opportunities to innovate in…
FDA approves remestemcel-L-rknd for steroid-refractory acute graft ver
On December 18, 2024, the Food and Drug Administration approved remestemcel-L-rknd (Ryoncil, Mesoblast, Inc.), an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy, for steroid-refractory…
